Deborah Pencharz

Deborah Pencharz

Auto-generated profile, based on publicly available information

Deborah Pencharz

Department of Nuclear Medicine, The Royal Free Hospital, Royal Free London NHS Foundation Trust, Pond Street, London, NW3 2QG, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in British Journal of Radiology
Verified
Journal Article
Closed access
DPDeborah Pencharz
Deborah Pencharz
GGGopinath Gnanasegaran
Gopinath Gnanasegaran
SNShaunak Navalkissoor
Shaunak Navalkissoor
Theranostics and its principles: pre-treatment selection of patients who are most likely to benefit from treatment by the use of a related, specific diagnostic test are integral to the treatment of patients with neuroendocrine tumours (NETs). This is due to NET’s important, but variable, somatostatin receptor (SSTR) expression, their heterogeneity and variation in site of primary and rate of progression. Only patients whose tumours have sufficient expression of SSTRs will benefit from SSTR based radionuclide therapy and demonstrating this expression prior to therapy is essential. This article provides a relevant overview of NETs and the multiple facets of SSTR based theranostics, including imaging and therapy radionuclides; clinical efficacy and toxicity; patient selection and treatment and finally emerging radiopharmaceuticals and newer clinical applications.

1 February 2019 in Clinical Radiology
Verified
Journal Article
Open access
DPD. Pencharz
D. Pencharz
JDJ. Dunn
J. Dunn
SCS. Connor
S. Connor
ASA. Siddiqui
A. Siddiqui
NSN. Sriskandan
N. Sriskandan
TST.A. Szyszko
T.A. Szyszko
To analyse the maximum standardised uptake value (SUVmax) ratio between tonsils in patients with and without tonsillar carcinoma to determine useful diagnostic thresholds. Positron-emission tomography (PET)/computed tomography (CT) examinations of patients with suspected head and neck squamous cell carcinoma (SCC) and controls from April 2013 to September 2016 were reviewed retrospectively. Tonsillar SUVmax ratios (ipsilateral/contralateral for malignant tonsils, maximum/minimum for patients without [controls]) were calculated and used to construct a receiver operating characteristic (ROC) curve. Twenty-five patients had tonsillar carcinoma (mean SUVmax ratio of 2, range 0.89-5.4) and 86 patients acted as controls (mean SUVmax ratio of 1.1, range 1-1.5). Using the ROC, the most accurate SUVmax ratio for identifying malignancy was >1.2 (77% sensitivity, 86% specificity). A potentially more clinically useful SUVmax ratio is ≥1.6 with 62% sensitivity and 100% specificity. An SUVmax ratio between tonsils of ≥1.6 is highly suspicious for SCC and could be used to direct site of biopsy. Some malignant tonsils had normal FDG uptake; therefore, PET/CT should not be used to exclude tonsillar cancer. Minor asymmetrical uptake is frequently seen in non-malignant tonsils and does not necessarily require further investigation. Due to the single centre nature of this study and the recognised variation in SUV measurements between PET scans, other centres may need to develop their own cut-offs.

1 September 2013 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
DPDeborah Pencharz
Deborah Pencharz
AQAnn-Marie Quigley
Ann-Marie Quigley
MHMargaret Hall
Margaret Hall
TWThomas Wagner
Thomas Wagner

1 March 2022 in Clinical Radiology
Verified
Journal Article
Closed access
DPD. Pencharz
D. Pencharz
SMS. Modi
S. Modi
SBS. Bandyopadhyay
S. Bandyopadhyay
UAU. Alhun
U. Alhun
NMN. Marchbank
N. Marchbank
TWThomas Wagner
Thomas Wagner

2 August 2018
Verified
Book Chapter
Closed access
PDF file
DPDeborah Pencharz
Deborah Pencharz

4 November 2022 in Clinical Radiology
Verified
Journal Article
Closed access
PDF file
SESherif Elsobky
Sherif Elsobky
AKAnthousa Kythreotou
Anthousa Kythreotou
DPDeborah Pencharz
Deborah Pencharz